Chardan Capital Upgrades Axovant Sciences (AXGT) to Buy
Chardan Capital upgraded shares of Axovant Sciences (NASDAQ:AXGT) from a neutral rating to a buy rating in a report issued on Monday morning, MarketBeat Ratings reports. They currently have $4.00 price objective on the stock.
“We upgrade Buy (low conviction), maintaining our price target at $4/share. This morning, Axovant announced updates from 2 of its clinical programs, showing: (1) encouraging interim results at 3 months from Cohort 1 (lower dose of 4.2×10^6 the phase II SUNRISE-PD trial (NCT03720418) of AXO-Lenti-PD gene therapy (GT) in Parkinson’s disease (PD), and (2) 3- month data showing enzyme activity in an investigator-initiated study (dose of 1.0x 10^14 vg) of AXO-AAV-GM2 GT in Tay-Sachs disease.”,” Chardan Capital’s analyst wrote.
Separately, Guggenheim began coverage on shares of Axovant Sciences in a report on Friday, February 15th. They issued a buy rating and a $7.00 target price on the stock.
Axovant Sciences (NASDAQ:AXGT) last posted its earnings results on Thursday, February 7th. The company reported ($0.27) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.27). On average, equities analysts forecast that Axovant Sciences will post -1.23 earnings per share for the current fiscal year.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics in the fields of neurology and psychiatry. Its therapeutic focus are Parkinson’s Disease and Lewy Body Dementia. It operates through the following geographical sgements: United States, Switzerland, Bermuda, and Other.
See Also: What is a bull market?
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.